Skip to main content
Equibles

Shelby

Analyst

RBC Capital Markets

Equibles does not estimate personal net worth.

About Shelby

Shelby is recorded as Analyst at RBC Capital Markets. Shelby has spoken on 6 earnings calls and 1 other investor event across 7 companies, most recently for Agios Pharmaceuticals, Inc. on September 9, 2026. Those appearances were for Agios Pharmaceuticals, Inc. (AGIO), REGENXBIO Inc. (RGNX), uniQure N.V. (QURE), Arrowhead Pharmaceuticals, Inc. (ARWR), Alnylam Pharmaceuticals, Inc. (ALNY) and 2 other companies. The companies whose calls Shelby spoke on are classified in the Healthcare sector.

Shelby on recent calls

“Maybe on the commercial preparation for a potential launch in sickle cell, I believe this has a higher Medicaid mix versus thalassemia and PKD. So one, is that correct?”
Analyst — RBC Capital Markets, Cantor Global Healthcare Conference (Fireside Chat) ·
“Maybe on DMD, I believe you said the BLA will include a combined safety data set for over 60 patients and then 12-month functional data for at least half of the pivotal cohort.”
Analyst — RBC Capital Markets, REGENXBIO Inc. Q2 FY2026 Earnings Call ·
“Maybe on the regulatory setup for Huntington's, appreciate different indications, but the recent FDA briefing documents ahead of ADCOMS for Capricor and Replimune did raise some pointed questions about the efficacy of both drugs.”
Analyst — RBC Capital Markets, uniQure N.V. Q2 FY2026 Earnings Call ·
“Yesterday, AstraZeneca printed a pretty meaningful miss for TTRPN, and we knew it was actually down 35% Q over Q. So I guess from a competitor standpoint. Is Al Nilem a net beneficiary of that mess in PN?”
Analyst — RBC Capital Markets, Alnylam Pharmaceuticals, Inc. Q1 FY2026 Earnings Call ·

Affiliation history

  • RBC Capital Markets

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity